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ABSTRACT   
A robust humoral immune response against human factor FVIII (hFVIII) following naked 
DNA transfer into immunocompetent hemophilia A mice completely inhibits circulating FVIII 
activity despite initial high-level hFVIII gene expression.  To prevent this undesirable response, 
we compared transient immunomodulation strategies.  Eight groups of mice (n=4-9/group) were 
treated with naked DNA transfer of pBS-HCRHPI-hFVIIIA simultaneously with 
immunosuppressive reagents that included Cyclosporine A (CSA); Rapamycin (RAP); 
Mycophenylate mofetil (MMF); combination of CSA and MMF; combination of RAP and MMF; 
a monoclonal antibody against murine CD40 ligand (MR1); recombinant murine Ctla4Ig; and 
combination of MR1 and Ctla4Ig.   All animals except those receiving only CSA exhibited 
delayed or absent immune responses against hFVIII.  The most effective immunosuppressive 
regimen, the combination of Ctla4Ig and MR1, prevented inhibitor formation in 8/9 animals; the 
ninth had a transient low titer antibodies.  All 9 mice of this group produced persistent, therapeutic 
levels of hFVIII for >6 months.  When challenged with the T dependent antigen, bacteriophage 
Φx174, tolerized mice exhibited normal primary and secondary antibody responses, suggesting 
that transient immunomodulation to disrupt B/T cell interaction at the time of plasmid injection 
effectively promoted long-term immune tolerance specific for hFVIII.  
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INTRODUCTION 
Hemophilia A is a congenital bleeding disorder caused by a deficiency of coagulation factor 
VIII (FVIII).  Currently hemophilia patients are treated with repeated infusions of plasma-derived 
or recombinant FVIII protein concentrates.  Gene therapy is expected to provide a more beneficial 
and cost effective treatment for this disease.  We have demonstrated previously that naked DNA 
transfer of a liver-specific, high-expressing plasmid (pBS-HCRHPI-hFVIIIA) into Rag2(-/-) 
severe combined immune deficient (SCID) mice led to persistent high-level expression of human 
factor VIII (hFVIII)
1.  Supra-physiologic expression levels of hFVIII were also achieved in 
immunocompetent hemophilia A mice, leading to complete but transient phenotypic correction 
during the first few days post gene therapy treatment.  However a strong humoral immune 
response against hFVIII subsequently completely inhibited circulating hFVIII activity in 
immunocompetent hemophilia A mice
2.   
The formation of inhibitory antibodies to infused hFVIII represents a major complication in 
the clinical treatment of hemophilia A patients.  A similar problem is predicted to occur following 
gene therapy for hemophilia A.  Various strategies have been explored to modulate the immune 
responses in hFVIII-treated hemophilia patients and in hemophilia A murine models undergoing 
repetitive hFVIII protein delivery.  High dose tolerance induction protocols are very expensive 
and only partially effective
3,4.  Anti-CD40L
5, cyclosporine A
6, and Rituximab
7,8, have each been 
successfully used to treat acquired Hemophilia A in individuals who developed anti-FVIII 
autoantibodies.  A partial suppressive response has been achieved in a group of hemophilia A 
patients using a combination of high dose hFVIII tolerance induction, and cyclophosphamide, 
with or without concomitant IVIG therapy
9,10. Notably, both the immune response to hFVIII and 
the effectiveness of immunomodulation appear to differ significantly in patients with congenital 
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and those with acquired hemophilia A, with more frequent responses and better results in the 
acquired cases. This difference is likely related, at least in part, to the sustained presence of 
circulating hFVIII antigen in the latter group of patients.  In hemophilia A mice, acquisition of 
inhibitors requires expression of the B7 co-stimulating molecule because treatment with Ctla4-Ig 
transiently blocks the response to repeated hFVIII protein infusion
11.  Treatment with anti-CD40L 
to disrupt signaling via CD40 also delays anti-hFVIII antibody formation in this model
12,13.  
However, long term tolerance has not been achieved in any of these animal models
12,13.  Recently 
several new strategies to prevent the production of inhibitory antibodies have also been reported, 
including high doses of FVIII to inhibit FVIII-specific memory B cells 
14, oral feeding of FVIII-
C2 domain 
15,   lipopolysaccharide (LPS)-activated B-cell blasts transduced with a fusion IgG 
containing the C2 or A2 domains of FVIII 
16,   and ex vivo transduction of hematopoietic stem 
cells 
17.   
In the hFVIII gene transfer mouse model using naked DNA of a liver-specific, high-expressing 
hFVIII plasmid previously established in our laboratory
2, the expression of hFVIII leads to a 
predominantly Th2 immune response associated with high-titer anti-hFVIII antibodies that persist 
for the life of the animals.  In this report, we have evaluated and compared multiple candidate 
immune suppression strategies designed to modulate or prevent the generation of hFVIII-specific 
T and B cells and the production of high affinity inhibitory antibodies of the IgG isotype.  To 
accomplish this, we designed protocols to eliminate or reduce key effector populations (antigen-
specific B and CD4+ T cells), modulate T-helper cell activation, alter T/B cell interactions, or 
inhibit specific pathways of T and /or B lymphocyte activation.  Immuno-modulation strategies 
were designed to meet the following criteria: (1) only transient exposure to immunosuppression; 
(2) inhibition of one or more critical B and/or T cell activation pathways; (3) induction of minimal 
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cytoablation and other associated toxicity; and (4) minimal effects on immune competence. These 
experimental criteria are essential for the translation of such protocols into human gene therapy 
trials.  We demonstrate that suppression of immune responses against FVIII is most effectively 
achieved by combined immunomodulation therapy at the time of hFVIII plasmid transfer using a 
combination of murine Ctla4-Ig and anti-murine CD40L (MR1), and most importantly, that 
transient inhibition of co-stimulatory molecules can promote long-term immune tolerance that is 
specific for hFVIII allowing long-term gene correction in immunocompetent hemophilia A mice.   
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MATERIALS AND METHODS 
Construction of Vectors.  The construction of pBS-HCRHPI-hFVIIIA containing a B-domain 
deleted human factor VIII cDNA
18 has been described previously
1.   
Animal Experiments. Animals were kept according to the National Institutes of Health guidelines 
for animal care and the guidelines of the Children’s Hospital and Regional Medical Center, 
Seattle.  Hemophilia A mice in 129/SV x C57BL/6 mixed genetic background were prepared by 
targeted disruption of exon 16 of the FVIII gene and provided by Drs. Rita Sarkar and Haig 
Kazazian Jr. at the University of Pennsylvania
19.  All the mice were housed under specific 
pathogen free conditions at the vivarium of the Children’s Hospital and Regional Medical Center.    
Immunosuppressive drugs and antibody.  Antibody against murine CD40L was a kind gift from 
Dr. Randolph J. Noelle at the Dartmouth Medical School, Lebanon, NH.  Murine Ctla4-Ig was 
produced by BD Pharmingen (San Diego, CA), Cyclosporin A (CSA) by Bedford Laboratories 
(Bedford, Ohio), rapamycin (RAP) by Wyeth-Ayerst laboratories (Madison, NJ), and 
mycophenolate mofetil (MMF) by Hoffman-La Roche Inc. (Nutley, NJ).    
Delivery of plasmid DNA and immunomodulating agents.  The methods of plasmid DNA 
preparation and DNA infusion have been described previously
1,2.  Briefly, 50 micrograms of 
hFVIII plasmids in 2ml phosphate buffered saline were injected into the tail vein of 20-24g FVIII 
knock out mice over 6-8 seconds
20-22.  Scheduled blood samples were taken from the retro-orbital 
plexus.   
Following plasmid injection, mice selected for transient immunosuppression received the 
immunomodulation components intraperitoneally according to the dosage and schedule listed in 
Table 1.  Combination therapy was given using the same schedule and dosages as the single agent. 
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Assays for measuring Human factor VIII antigen and its activity.   hFVIII antigen levels were 
examined by ELISA using ESH4/ESH8 monoclonal antibodies (American Diagnostica Inc., 
Greenwich, CT) against hFVIII which are species-specific, and do not cross-react with murine 
factor VIII.  The background antigen level of hFVIII in untreated control mice was negligible. 
Serially diluted normal human plasma was used as standard.   hFVIII activity was quantitated by a 
chromogenic assay (COATEST, measuring factor Xa generation; Chromogenix AB, Sweden), and 
a modified clotting assay utilizing activated partial thromboplastin time (APTT) reagent and factor 
VIII deficient plasma. hFVIII levels were calculated from a standard curve generated by using a 
series of dilutions of normal human pooled plasma.   
Assays for anti-hFVIII antibodies and their subclasses.  Inhibitory antibodies were measured by 
hFVIII Bethesda assays as previously described
23. Total antibodies against hFVIII were detected 
by an antigen-specific ELISA technique using a plasma derived, monoclonal antibody-purified 
commercial factor VIII protein concentrate (Monarc-M, American Red Cross, prepared by Baxter 
Healthcare Corporation, Glendale, CA) and horseradish peroxidase-conjugated monoclonal 
antibodies against total murine IgG as described
1. 
Evaluation of hFVII-specific IgG subclasses.  Antigen-specific IgG subclasses were evaluated by 
ELISA using hFVIII coated plates and horseradish peroxidase-conjugated antibodies for different 
murine IgG subclasses, including IgG1, IgG2a, IgG2b, and IgG3 (Roche Diagnostics Corp., 
Indianapolis, IN).  The microtiter plates (Corning Inc., Corning, NY) were coated with purified 
human factor VIII protein (20U/ml [1U=100ng human factor VIII protein], Monarc-M) which had 
been extensively dialyzed against 50mM Imidazole buffer to remove low molecular weight 
additives.  Plasma taken at different time points from plasmid-treated mice was diluted (1:100) 
and applied to the coated wells.  Following incubation and extensive washing, antibodies of 
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different IgG subclasses were added, followed by incubation with o-phenylenediamine 
dihydrochloride substrate. A standard curve for the different IgG subclasses was established using 
serially diluted mouse immunoglobulin reference serum (Bethyl Laboratories, Montgomery, TX).  
The background levels of hFVIII-specific IgG subclasses measured in untreated hemophilia A 
mice were negligible (<10ng/ml).  
Cytokine production and proliferation assay by stimulated spleen cells.    Spleens were removed 
aseptically from hemophilia A mice 180 days post plasmid and Ctla4-Ig and MR1 treatment, and 
single cell suspensions prepared in RPMI 1640 medium (Invitrogen) containing 2mM glutamine, 
50µM 2-mercaptoethanol (2-ME), 100U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal calf 
serum.  Naïve hemophilia A mice were used as controls.  Red blood cells were lysed with sterile 
17mM Tris and 140mM NH4Cl buffer, pH 7.4.   For cytokine production assays, isolated spleen 
cells (1 x 10
5 cells/200µl/well) were stimulated on day 0 with 10µg/ml Phytohemagglutinin (PHA) 
or 20U/ml hFVIII protein (Monarc-M which had been extensively dialyzed against 50mM 
Imidazole buffer as described above) or 4µg albumin in imidazole buffer as control.  Culture 
supernatants were collected over a six day period and stored at -80
oC. IL-2, interferon-γ and IL-10 
were determined by ELISA using specific antibodies and standards purchased from BD 
Pharmingen (San Diego, CA).  For assessment of proliferation, triplicates of isolated spleen cells 
(1 x 10
5 cells/200µl/well) from hemophilia A mice one year post plasmid injection and Ctla4-Ig 
and MR1 treatment were stimulated with 10µg/ml Phytohemagglutinin (PHA) or 1-20U/ml 
hFVIII protein for three days.  
3H-thymidine was then added and cell cultures were harvested 18 
hours later.  The incorporation of 
3H-thymidine was measured and the results of triplicates 
expressed as mean counts per minute (cpm).  The data presented (Δcpm) were the mean Cpm 
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minus background Cpm.  For both assays, plasmid-treated and naive untreated hemophilia A mice 
were used as controls. 
Immunization with bacteriophage Фx174.  Bacteriophage Фx174 was prepared as previously 
described 
24. The stock solution of 1x10
11 plaque-forming units (PFU) per ml was diluted and 
injected intraperitoneally into tolerized and un-tolerized mice six months post-plasmid injection at 
a dose of 1x10
10PFU/kg (2x10
8PFU/mouse).  A secondary immunization followed four weeks 
after the primary immunization.    
Approximately 200µl of blood were collected before immunization, and 1, 2, and 4 weeks 
after each immunization.  Aliquots of serum were stored at -80
oC and subsequently analyzed for 
phage-neutralizing antibody activity, expressed as the rate of phage inactivation (Kv) using the 
standard formula
24: Kv=(dilution of serum/time of phage-serum incubation in minutes) x ln(phage 
assay PFU at time 0 min/phage assay PFU at time 60 min). 
Statistical Analysis.  For comparisons of animals developing inhibitory antibodies with control 
animals, the Unpaired Student t test was performed, and P < 0.05 was considered statistically 
significant. 
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RESULTS 
We have shown previously that hemophilia A mice mount a T cell-dependent humoral 
immune response to exogenous hFVIII following naked gene transfer of pBS-HCRHPI-hFVIIIA, 
and that pretreatment with cyclophosphamide induced long-term tolerance in one of six treated 
animals
2.  The other five mice had delayed responses compared to untreated animals but still 
developed high-titer inhibitory antibodies.   
Transient suppression of the inhibitory response with a single immunosuppressive agent.   In order 
to develop a more effective immunomodulatory regimen, we evaluated the immunosuppressive 
effects of single agents on the formation of inhibitory antibodies to hFVIII following nonviral 
gene transfer.  After rapid injection of 50 µg of hFVIII plasmid in 2 ml saline into the tail vein, 
groups of mice were treated with either cyclosporine A (CSA), rapamycin (RAP), or 
mycophenolate mofetil (MMF) according to the dose and schedule listed in Table 1.  The mice 
treated with CSA produced high levels of hFVIII in the first two weeks following gene transfer, 
but then dropped to undetectable levels within the next few days (Fig. 1C), concomitant with the 
appearance of antibody formation (Fig. 1D).  This pattern is indistinguishable from that observed 
in plasmid-treated mice without immunomodulation (Fig. 1A & B).  Mice treated with RAP had a 
slightly delayed immune response with inhibitory antibodies appearing at 3-4 weeks post plasmid 
delivery.  Eventually, however, the hFVIII concentrations dropped to undetectable levels with the 
appearance of high-titer inhibitory antibodies as shown in Fig. 1E&F.  Among the three single 
agent regimens, MMF was most effective in suppressing the immune responses against hFVIII.  
Two of the four mice treated with MMF had a significantly delayed immune response with high-
titer antibody appearing 4-8 weeks post plasmid delivery when hFVIII levels dropped to 
undetectable levels (Fig. 1G&H).  The other two mice developed very low-titer inhibitory 
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antibodies 4 weeks post plasmid delivery and had a gradual drop of functional hFVIII levels 
which stabilized at ~20% of normal levels during the observation period of 180 days following 
plasmid delivery (Fig. 1G&H).      
Antigen specific IgG subclasses following single immunosuppressive agent therapy.  It has been 
shown previously that the majority of anti-hFVIII IgG in this model is of the IgG1 isotype, 
however small amounts of anti-hFVIII antibodies of the IgG2a, IgG2b, and IgG3 isotype were 
also detected.  These findings suggest that transgene-specific antibodies are predominantly 
generated in response to Th2 induced activation signals.   
To further characterize the nature of the immunosuppressive effect, we examined the anti-
hFVIII IgG subclass specificity using an ELISA based assay in plasmid-treated mice receiving 
single-agent immunomodulation therapy (Fig. 2).  Treatment with CSA did not significantly alter 
the production of any antigen-specific IgG isotype except for a slight reduction of the IgG3 
isotype antibodies. RAP treatment considerably reduced the production of IgG2b and IgG3 but not 
IgG1 and IgG2a isotypes.  The two MMF treated animals that exhibited long-term hFVIII 
expression and low-titer inhibitory antibodies did not generate detectable levels of inhibitors of 
any IgG isotype.  The other two MMF treated animals which produced high-titer inhibitors had a 
reduction in IgG1 and IgG2b but not in IgG2a and IgG3 antigen-specific isotypes.    
Combination immunosuppressive therapy with CSA/MMF or RAP/MMF.  To further suppress the 
inhibitory antibody response to hFVIII, we explored the effects of combining two 
immunosuppressive agents, e.g., CSA plus MMF, and RAP plus MMF, respectively.  While 
delayed and reduced immune responses were observed in either of the combination therapy, high-
titer inhibitory antibodies eventually developed and eliminated functional hFVIII levels in all 
treated animals (Fig.1I, J, K & L).  Surprisingly, the combination therapies appeared to be less 
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effective than MMF alone. It is unclear whether these differences reflect heterogeneity in the 
humoral immune response to hFVIII as has been observed by others, or another mechanism that 
reduces the efficacy
12,25-27. Because the hemophilia A mice used in these studies are of mixed 
genetic background (129sv x C57BL/6), the resulting heterogeneity may have contributed to this 
variability. 
Immunomodulation therapy with Ctla4-Ig, anti-CD40L mAb (MR1) or a combination of both 
agents.  Three groups of plasmid pBS-HCRHPI-hFVIIIA treated mice were evaluated (Fig. 3):  
group 1 (n=8) was injected with recombinant murine Ctla4-Ig (Fig. 3A); group 2 (n=9) with MR1, 
a monoclonal antibody against murine CD40 ligand (Fig. 3C); and group 3 (n=9) with the 
combination of MR1 and Ctla4-Ig (Fig. 3E).  When compared with plasmid-injected mice without 
immunomodulation (Fig. 1A&B), treated mice from all groups showed delayed immune responses 
to hFVIII. Animals treated with Ctla4-Ig alone developed inhibitors 2-4 weeks post-injection (Fig. 
3B) and all showed rapid loss of FVIII activity (Fig. 3A). Six of 9 animals treated with MR1 
developed inhibitors at 4-6 weeks post treatment; among these, one mouse died after developing 
high-titer inhibitors at 4 weeks post treatment.  Of the remaining three, one had a significantly 
delayed response but eventually developed high-titer inhibitors at 10 weeks; one mouse developed 
low-titer antibody at 11 weeks post treatment; and the other failed to develop inhibitors and 
produced supraphysiologic levels of hFVIII throughout the observation period.  Most notably, 8 
of 9 animals treated with the combination regimen of MR1 and Ctla4-Ig failed to develop 
detectable inhibitors for at least 20 weeks (Fig. 3F). The ninth animal developed transient, low-
titer inhibitory antibodies that partially blocked the functional activity of hFVIII in plasma.  All 
animals treated with the combination of MR1 and Ctla4-Ig exhibited persistent, therapeutic or 
supra-physiologic levels of circulating hFVIII protein for more than 140 days (Fig. 3E), 
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demonstrating that transient immunomodulation given at the time of gene transfer can induce 
long-term tolerance following gene therapy.  In addition, the expression levels of FVIII and 
inhibitor titers were followed in three tolerized mice for up to one year; no significant changes 
were observed compared to those obtained at 5 months post treatment.   
Antigen specific IgG subclasses following combination immunomodulation therapy.  We similarly 
evaluated the anti-hFVIII IgG subclasses in the plasmid-treated mice exposed to Ctla4-Ig and/or 
anti-CD40L mAb (MR1) (Fig. 4).   Treatment with Ctla4-Ig alone slightly reduced the production 
of IgG2b, and more significantly IgG3, but did not alter significantly the production of IgG1 and 
IgG2a isotypes. MR1 treatment considerably reduced production of IgG2a, IgG2b, and IgG3, and 
moderately reduced the production of IgG1.  As expected, mice treated with the combination of 
Ctla4-Ig and MR1 had undetectable levels of all four IgG isotypes, suggesting a synergistic 
interaction between these two agents.   
Cytokine release and proliferation assay following gene transfer and combination 
immunomodulation therapy.  T cell responses were evaluated by an in vitro proliferation assay in 
response to a wide range of hFVIII concentrations using splenocytes collected from mice at one 
year post plasmid treatment.  Cells isolated from mice treated with hFVIII plasmid had 
significantly higher proliferation rates compared to those from tolerized mice treated with hFVIII 
plasmid and combination therapy of Ctla4-Ig and MR1 and untreated mice (Figure 5). The 
proliferative response is dependent on the hFVIII concentration in the culture medium.  T cell 
responses initiated by in vitro exposure to hFVIII were also examined using cytokine profiling of 
splenocytes collected from mice at six months post plasmid treatment.  Cytokine production by 
splenic T cells isolated from plasmid-treated and untreated hemophilia A mice are shown in Fig. 6.  
Both groups of animals produced large quantities of lymphokines following PHA stimulation.  IL-
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10 secretion in response to hFVIII was significantly higher in plasmid-treated hemophilia A mice 
compared with untreated mice, whereas IL2 and IFN-γ production was only slightly increased.  
These findings are consistent with a Th2 dominant immune response to hFVIII in this model. 
These results are comparable to those seen in animals that were challenged with hFVIII protein
28.  
Most importantly, mice tolerized by the combination therapy with Ctla4-Ig and MR1 showed 
neither an increase in cytokine production nor enhanced T cell proliferation when stimulated with 
hFVIII.   
Long-term immune tolerance is specific for hFVIII.  To evaluate whether short-term 
immunomodulation led to long-term defects in host immune function, animals were challenged 
six months post plasmid injection with the T dependent neoantigen, bacteriophage Φx174
29.  
Three groups of mice (n=2/group) were immunized twice, four weeks apart, including 
tolerized mice treated with plasmid DNA and a combination of Ctla4Ig and MR1, mice treated 
with plasmid only, and untreated control mice.  As shown in Figure 7, animals tolerized to 
hFVIII exhibited a normal primary and secondary responses to bacteriophage Φx174 showing 
a strong amplification of antibody titers and isotype switching, comparable to antibody 
responses observed in mice treated with plasmid only and exhibiting high-titer inhibitory 
antibodies, and to those of control untreated mice.  These results strongly suggest that transient 
inhibition of co-stimulatory molecules in hFVIII plasmid-treated hemophilia A mice can 
promote long-term immune tolerance that is specific for hFVIII without altering immune 
responses to other T cell dependent antigens. 
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DISCUSSION 
Naked gene transfer of hFVIII into the liver of hemophilia A mice is an effective technique to 
generate high level of functional hFVIII. However, hFVIII activity declines rapidly within two 
weeks post plasmid delivery. At the same time, sustained hFVIII protein expression can be readily 
detected in the mouse livers for a minimum of six months as demonstrated by immunostaining 
using anti-hFVIII antibody
2.  The decline of functional hFVIII protein is directly related to the 
appearance of high-titer inhibitory anti-hFVIII antibodies of the IgG isotype that appear two 
weeks post plasmid treatment and last for the lifetime of these animals.  The immune responses 
induced in hFVIII plasmid-treated hemophilia A mice are primarily humoral responses and 
include antigen specific B and T cells; there is no evidence for the induction of cytotoxic T 
lymphocytes (CTLs).  This antibody response is very similar to that in hemophilia mice treated 
with repeated protein infusions
28, and to that observed in hemophilia patients with inhibitors
30.  
The majority of anti-hFVIII antibody in the plasmid-treated mice is of the IgG1 isotype, but 
IgG2a, IgG2b, and IgG3 antibodies are also present. These findings suggest that the immune 
response in these animals is mediated mainly by Th2-induced signals.  Most notably, by using 
“naked gene transfer”, it is unlikely that these immune responses are driven or potentiated by viral 
vector components as we observe little decline in plasmid containing hepatocytes over time.  This 
model therefore represents an excellent system to study inhibitory antibody formation generated 
via persistent transgene expression, and permits us to investigate potential immunomodulation 
strategies designed to prevent or eliminate the formation of inhibitory antibodies against hFVIII.    
In established animal models of tolerance, the presence of antigen appears to be required to 
maintain the tolerant state. Previous studies suggest that the minimal number of FVIII required to 
maintain hyporesponsiveness is in the range of 10
-11-10
-10M per mouse
31,32, a level readily 
For personal use only. on November 6, 2014.  by guest    www.bloodjournal.org From   16
achieved by the sustained hFVIII gene expression (10
-9-10
-8M) in our animal model.  Based upon 
this concept, high-dose tolerance protocols have been utilized since the 1970s in efforts to tolerize 
hemophilia patients to infused hFVIII. As mentioned earlier, this approach has also been 
combined with the long-term use of immunosuppressive agents. However, such protocols are 
costly and have been successful only in patients with low titer inhibitors. 
We used the model of long-term expression of hFVIII following naked plasmid delivery to 
explore the effect of combining the administration of plasmid DNA with transient 
immunosuppression to induce long-term tolerance in hemophilia A mice.  As has been shown 
previously
2, the administration of the cytotoxic and immunosuppressive agent cyclophosphamide 
following pBS-HCRHPI-hFVIIIA injection resulted in the prevention (1/6 animals) or delay (5/6 
animals) of inhibitory antibody formation against the transgene.  The complete and sustained 
phenotypic correction of hemophilia A achieved in one animal following transient 
immunomodulation with cyclophosphamide lasted for greater than 6 months, strongly suggesting 
that consistent tolerance to this “neoantigen” and adequate expression of functional hFVIII might 
be achievable with an optimized immunosuppressive regimen.      
We therefore evaluated multiple immunosuppressive strategies (Table 2) designed to prevent 
and/or modulate the generation of hFVIII-specific T-cells and the production of inhibitory 
antibodies by hFVIII specific B cells without induction of nonspecific tolerance. We first 
evaluated single agents that target the signaling events essential for sustained T cell activation. 
Cyclosporine A (CSA) inhibits proximal T-cell receptor (TCR) dependent signals, thereby 
suppressing the early stages of lymphocyte activation. This agent is used routinely in a broad 
range of applications including humans with acquired hFVIII inhibitory antibodies. The bacterial 
macrolide, rapamycin (RAP), is a potent immunosuppressant and a promising anti-cancer drug. In 
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forming a complex with its cellular receptor, the FK506-binding protein (FKBP12), RAP binds 
and inhibits the function of the mammalian target of rapamycin (mTOR).  RAP inhibits T cell 
proliferation following mitogen (PHA) and/or alloantigen (MLR) stimulation. Currently, no 
published experience with RAP exists in human hemophilia or related animal models.   
Mycophenolate mofetil (MMF) as well as cyclophosphamide were used for nonspecific inhibition 
of B and T cell proliferation and the production of antibodies. MMF is approved for the 
prevention of renal transplant rejection and is used to treat a wide range of autoimmune disorders. 
Our results demonstrate that neither single agent nor combined therapy with any of these three 
agents was sufficient to prevent antibody formation against hFVIII, although treatment with MMF 
considerably suppressed the production of antigen-specific IgG1 and IgG2b antibodies; the effect, 
however, was not potent enough to prevent the induction of long-lasting inhibitory antibodies.   
Because an effective antibody response to a protein antigen requires the interaction of antigen 
presenting cells (APC) with T and B cells, we next explored the effects of blocking the T/B cell 
interaction by interfering with the known co-stimulatory pathways CD40L/CD40 and B7/CD28 
(CTLA-4).  Two specific agents, with comparable compounds currently under evaluation in 
human clinical trials, were evaluated. CTLA4-Immunoglobulin (CTLA4-Ig) is a soluble fusion 
protein that was created by fusion of the extracellular domain of CTLA4 to the heavy chain 
constant regions 2 and 3 of IgG1.  CTLA4 itself is a high-affinity receptor for both the B7-1, and 
B7-2 ligands.  CTLA4-Ig binds strongly to the B7-1 and B7-2 ligands altering the interaction of 
B7 with CD28 of this co-stimulatory pathway, thus initiating a potent down-modulatory effect. 
CTLA4-Ig has been used successfully as immunosuppressive regimen in animal models of 
autoimmunity
33 and transplantation
34 and, at least transiently, blocks the inhibitor formation in 
hemophilia A mice
11.  The interaction of CD40L expressed by activated CD4
+ T cells with 
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constitutively expressed CD40 on B cells is essential for the generation of high affinity antibody 
of different isotypes
35.  Anti-mouse CD40L monoclonal antibody (mAb) has been used previously 
to transiently block the inhibitory antibody formation in hemophilia A mice
12.  Anti-mouse 
CD40L mAb alone or the combination of anti-mouse CD40L mAb and soluble murine Ctla4-Ig 
have been used to facilitate adenovirus-mediated transgene expression after both primary and 
secondary vector administration
36,37. 
Based on the limited effects observed with either Ctla4-Ig or anti-CD40L alone, we combined 
these two agents to simultaneously target both effector pathways to induce tolerance. As shown in 
Fig. 3, this combined immunotherapy regimen induced long-term tolerance in all treated animals. 
Only one of 9 mice developed low-titer antibodies that were transient and only partially blocked 
the functional activity of hFVIII in plasma. All 9 animals including the one with transient 
antibodies produced persistent, therapeutic or supra-physiologic levels of hFVIII expression. 
These results demonstrate that short term immunomodulation by blocking co-stimulation at the 
time of gene transfer can induce long-term tolerance against a specific neoantigen introduced by 
gene therapy.  Our findings differ from those reported by Jiang et al
38 who observed that local 
high-level adenovirus-mediated expression of Ctla4-Ig and CD40-Ig did not induce a state of 
permanent tolerance towards a foreign transgene, eGFP, in primary skeletal muscles.  These 
differences could be due to the presence of adenovirus related proteins, differences in the target 
organs involved (liver vs muscle), and/or the local vs systemic distribution of Ctla4-Ig and anti-
CD40L.  Another difference is that GFP is an intracellular protein, while FVIII is a secretory 
protein. 
Several hypotheses have been proposed to explain the strong combined inhibitory effects of Ctla4-
Ig and anti-CD40L.   Engagement of the T-cell receptor by antigen-MHC in the absence of co-
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stimulatory signals commonly produces T-cell anergy or prolonged unresponsiveness
39, and may 
result in prolonged and perhaps indefinite survival of allografted organs
40,41.    Patients with X-
linked hyper IgM Syndrome due to mutations of CD40L and mice treated with anti-CD40L mAb 
(MR1) are unable to signal via CD40 and as a result lack class switch recombination and somatic 
hypermutation
42,43.  During antigen challenge, the dominant effect of Ctla4Ig consists of blockade 
of CD28 binding by B7-1 or B7-2, therefore inhibiting further activation of T cells by activated B 
cells.   An alternative hypothesis may postulate that the induction and maintenance of tolerance by 
co-stimulatory blockade is the results of active suppression mediated by individual subsets of 
regulatory T cells (Treg) or cytokines.  In Ctla4-Ig and MR1 treated hemophilia mice, the 
“tolerance” was maintained along with high-level constitutive hFVIII gene expression.  To 
systematically test and delineate the mechanisms for tolerance induction in the mice treated with a 
combination of Ctla4-Ig and MR1, T cells isolated from tolerized mice have to be adoptively 
transferred into naive hemophilia A mice.  The recipient mice will subsequently be challenged by 
hFVIII plasmid injection to test for active suppression of the transgene-specific immune response.  
If the tolerance observed in the treated mice is induced by elimination of antibody production due 
to T-cell anergy or prolonged unresponsiveness, adoptive transfer of T cells will not induce 
tolerance in the recipient mice.  On the other hand, if the tolerance is the result of 
immunosuppression by regulatory T cells, adoptive transfer is expected to facilitate tolerance 
induction in the recipient mice.    
    Interestingly neither Ctla4-Ig nor anti-CD40L treatment alone achieved a significant 
inhibitory effect whereas the combined therapy induced long-term tolerance. This strongly 
suggests that the two compounds act synergistically in blocking distinct activation pathways.   
Furthermore T cells from tolerized mice remained non-responsive to hFVIII exposure in vitro 
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whereas plasmid treated hemophilia A mice not receiving combination therapy responded with 
strong IL-10 production (Fig. 6).   
In our experiments, Ctla4-Ig was less effective than MR1 when used alone in reducing the titer 
of anti-hFVIII antibodies.  This result is different from those obtained from immuno-modulation 
of adenoviral gene transfer of factor IX where Ctla4Ig was more effective than MR1
36,37.  In the 
latter case, the inhibitory response was primarily induced against viral vectors to generate 
predominantly cytotoxic lymphocyte (CTL) that led to destruction of transduced cells.  Therefore, 
blocking CD28 pathway is likely more effective to block T-cell dependent responses whereas the 
blocking of antibody production through CD40L pathway is less effective.  In contrast, in the 
plasmid-treated hemophilia A mice, the inhibitory response is predominantly a humoral response 
against the transgene product, hFVIII, and MR1 which blocks T help function is apparently more 
effective than Ctla4Ig alone for blockade of the antibody response.  CD40L also enhances APC 
function by inducing expression of the B7 proteins.  Thus, the synergistic effect of dual blockade 
of both CD28 and CD40L co-stimulatory pathways with Ctla4-Ig and MR1 induced long-term 
antigen-specific tolerance but not a general immunodeficiency, fulfilling the requirements listed in 
the introduction section.   
A clinical trial to induce tolerance is a logical next step to test the efficacy of combined 
immunomodulation therapy using CTLA4-Ig and anti-CD40L in humans.  CTLA4-Ig does not 
seem to induce permanent immune compromise in humans 
44 and has recently been approved by 
the FDA for clinical use.  Clinical trials to test efficacy and safety of anti-CD40L have yielded 
controversial results.  In particular, some trials induced thrombotic events or increased thrombotic 
risks in patients 
45,46, whereas some did not 
47.  In another study 
48, administration of heparin in 
conjunction with anti-CD40L also reduced the frequency of thromboembolic complications.  In 
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order to use this agent in humans, further studies are needed to delineate functional and safety 
profiles of different monoclonal antibodies targeting different CD40L epitopes and functions.  The 
minimum effective dose of anti-CD40L can first be tested in animals such as our mouse model.   
It will be important to compare our findings with other immunomodulation regimens, 
including a non-activating, non-depleting anti-mouse CD3 antibody to eliminate and/or tolerize 
specific T cell subsets, and a murine B cell depleting antibody that affects mature and transitional 
murine B-cells. Our goal is to develop the most effective immune modulating therapy with the 
least toxicity. It will be important to design an immunomodulation regimen that induces only a 
transient immunodeficiency in the host, as was the case in our combined immunomodulation 
treatment.  Additional experiments are required to explore whether transient immunosuppressive 
regimens can down regulate or eliminate a pre-existing immune response such as in mice that 
have already developed inhibitors. 
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Table 1..  Dosage and schedule of delivery for single immunosuppressive agents 
Agents      dosage and schedule* 
Cyclosporine A (CSA)  5mg/kg per day  (Day 0
† – 14) 
Rapamycin (RPA)    2mg/kg per day  (Day 0 – 14) 
Mycophenolate mofetil (MMF)  40mg/kg per day (Day 0 – 14)     
CTLA4-Ig    5mg/kg per day  (Day 0 and 2) 
Anti-CD40L (MR1)    10mg/kg per day at (Day –1, 0, 2, 7, and 14) 
 
*via intraperitoneal injection (IP). Combination regimens use the same combined 
schedule and dosages 
†Day 0 represents the day of plasmid injection. At day 0, the immunosuppressive agents 
were given following the plasmid injection. 
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Table 2.  List of Immunosuppressive agents.           
 
Published Experience 
in Hemophilia A 
Lineage  Agent Primary 
Mechanism of 
Action  Human 
Patients 
Murine 
Models 
Refs. 
Cyclophosphamide 
(CTX)
§ 
Non-specific cyto-
toxicity 
Clinical 
trials w. 
or w/o 
IVIG; 
Partial 
response
No report  9,10  B+ T 
Cells 
Mycophenylate 
mofetil (MMF)
 § 
IMPDH inhibition-
primarily inhibits 
B+T proliferation 
 
No 
report 
No report 
49 
Anti-CD20 
(Rituximab) 
Peripheral  
B Cell Depletion 
 
Case 
report 
No report 
7  B Cell 
Anti-CD40 Ligand 
(L), e.g. MR1
§ 
Blockade of CD40 
dependent 
immunoglobulin 
class switch, T-
helper dependent B 
cell activation 
No 
report 
Efficient 
blockade of 
inhibitor 
formation, 
Transient 
duration 
12,13,50 
 
Anti-CD3 
 
 
T cell depletion or 
partial activation 
leading to anergy 
No 
report 
No report 
51-53 
Cyclosporine A 
(CSA)
§,* 
 
 
 inhibition of TCR 
dependent signals  
Case 
reports 
No report 
6,54 
 
CTLA4-Ig
§ 
 
 Inhibition of T cell 
co-stimulation 
 
No 
report 
Efficient 
blockade of 
inhibitor 
formation, 
Transient 
55 
T cell 
Rapamycin (RAP)
§,* 
 
 
 
 M-TOR inhibition 
– blocks TCR 
signaling 
No 
report 
No report 
56,57 
§  Used in this study.
     *Also likely alter B cell activation.  Abbreviations: IVIG, intravenous 
immunoglobulin  ; IMPDH, inosine monophosphate dehydrogenase; TCR, T-cell receptor  ; M-TOR, 
mammalian target of rapamycin. 
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FIGURE LEGENDS 
 
Figure 1.  Naked plasmid transfer of hFVIII plasmids into hemophilia A mice with 
immunosuppressive agents.   hFVIII levels and inhibitory activity were assessed in hemophilia 
A mice after treatment with pBS-HCRHPI-hFVIIIA beginning on day 1.  No transient 
immunosuppression (A,B), CSA (C,D), RAP (E,F), and MMF (G,H).  Fifty μg of the plasmid in 
2ml saline solution was injected into the tail vein of mice (n=4) in 5-8 seconds. 
Immunosuppressive drugs were administered intraperitoneally for 14 days starting from the day of 
the plasmid injection.  Mice were then bled at regular intervals.  Circulating hFVIII activities in 
plasma were evaluated by a modified clotting assay (A, C, E, & G), and confirmed by a 
COATEST assay.  Inhibitory antibody titers were evaluated by Bethesda assay and are expressed 
as BU/ml (B, D, F, & H).  For transient immunosuppression with combined agents, CSA and 
MMF (I,J) and RAP and MMF (K,L) are shown.  Combined immunosuppressive drugs were given 
at the same schedule as the respective single agent (Table 1).  Each symbol represents an 
individual mouse’s results from both assays. 
 
Figure 2.  Subclasses of anti-hFVIII IgG immunoglobulin in hemophilia A mice after naked 
plasmid transfer of pBS-HCRHPI-hFVIIIA with or without single agent 
immunosuppression.  Titers of subclasses of IgG including IgG1, IgG2a, IgG2b, and IgG3 
produced at two months following gene transfer were determined by IgG subclass-specific ELISA.    
All animals treated as described in Figure 1 (A-H) were tested and their levels were averaged.  
 
Figure 3.  Naked plasmid transfer of hFVIII plasmids into hemophilia A mice with or 
without immunomodulation (co-stimulation blockade).   hFVIII levels and inhibitory antibody 
formation over time in hemophilia A mice after treatment with pBS-HCRHPI-hFVIIIA beginning 
on day 1. Transient immunomodulation included: Ctla4-Ig on days 1 and 2 (n=8 total; A,B);  MR1 
on days -1, 1, 2, 7 and 14  (n=9 total; C,D); and Ctla4-Ig
  with
 MR1 (n=9 total; E,F) using the 
same combined schedule and dosages as with each individual agent.  Fifty μg of the plasmid in 
2ml saline solution was injected into the tail vein of mice in 5-8 seconds. Two separate cohorts of 
animals (n=4-5/group) were used at separate times for each set of immunomodulation 
experiments; the data from two cohorts were combined and presented in the figure.  Respective 
immunosuppressive drugs were administered intraperitoneally at indicated times. # denotes the 
death of one treated mouse in (C).  Mice were bled at regular intervals.  Circulating hFVIII 
activities and inhibitory antibody titers were evaluated as in Fig 1.  
 
Figure 4.  Subclasses of anti-hFVIII IgG immunoglobulin in hemophilia A mice after naked 
plasmid transfer of pBS-HCRHPI-hFVIIIA with or without immunomodulation (co-
stimulation blockade).  Titers of subclasses of IgG including IgG1, IgG2a, IgG2b, and IgG3 
produced at two months following gene transfer were determined by IgG subclass-specific ELISA.    
All animals treated as described in Figure 3 were tested and their levels were averaged except that 
in the MMF-treated group, the IgG levels from only 3 mice that developed inhibitors were 
averaged.  
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Figure 5.  Proliferation assay following in vitro stimulation of T cells isolated from 
hemophilia A mice.  Two animals per group were untreated (n=2, -Δ-), hFVIII plasmid-treated 
(n=2, -o-), or hFVIII plasmid-treated receiving immunomodulation by combination of Ctla4 and 
MR1 (n=2, -▲-, animals from the group shown in Fig. 3E&F).  Splenic T cells were isolated from 
hemophilia A mice and cultured in the presence of hFVIII for three days.   T cell proliferation 
were measured in triplicate against a range of FVIII concentration.  Each data set represents the 
mean Δcpm obtained from two mice.  
 
Figure 6.  Cytokine production following in vitro stimulation of T cells isolated from 
hemophilia A mice.  Four animals per group were untreated, hFVIII plasmid-treated, or hFVIII 
plasmid-treated with immunomodulation by combination of Ctla4 and MR1 (4 animals from the 
group shown in Fig. 3E&F).  Splenic T cells were isolated from hemophilia A mice and incubated 
with hFVIII for six days.   Production of IL-2, interferon-γ (INF-γ) and IL-10 were measured from 
the culture media using ELISAs.    
 
Figure 7.  Bacteriophage challenge of hemophilia mice following naked gene transfer and 
transient immunomodulation.  Tolerized hemophilia A mice (n=2, -▲-), selected mice from the 
group shown in Fig. 3E&F) were challenged twice 4 weeks apart with the neoantigen, 
bacteriophage  Фx174 (2x10
8 PFU/each challenge).  Plasmid-treated (n=2, -o-), and untreated 
hemophilia A mice (n=2, -Δ-) were used as controls.  Phage-neutralizing antibody activity was 
expressed as the rate of phage inactivation (Kv) using a standard formula
24.  Mice not receiving 
bacteriophage did not produce neutralizing antibody (data not shown).   
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Miao et al., Figure 5
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Miao et al., Figure 7
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